research use only
Cat.No.S3569
| Related Targets | CXCR Nrf2 Mitophagy LRRK2 ULK FKBP Heme Oxygenase cGAS LC3 Cell wall |
|---|---|
| Other Autophagy Inhibitors | Resveratrol (trans-Resveratrol) Spautin-1 PIK-III DC661 Lys05 Trihydrochloride Autophinib SMER28 EN6 Flubendazole QX77 |
|
In vitro |
Water : 100 mg/mL
DMSO
: 20 mg/mL
(137.69 mM)
|
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 145.25 | Formula | C7H19N3 |
Storage (From the date of receipt) | 2 years -20°C liquid |
|---|---|---|---|---|---|
| CAS No. | 124-20-9 | -- | Storage of Stock Solutions |
|
|
| In vitro |
Spermidine and spermine significantly increases the viability and proliferation of SKOV-3 cells in a time-dependent manner, and decreases the apoptotic effect of Difluoromethylornithine (DFMO) in SKOV-3 cells. |
|---|---|
| In vivo |
Spermidine, a selective activator of TC45, rescues exacerbated phenotype of Hematopoietic stem and progenitor cells (HSPCs) in IFN‐γ‐treated Hemgn-/- mice. |
References |
|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06017219 | Active not recruiting | Healthy Subjects |
Chrysea Labs Lda |
May 5 2023 | Not Applicable |
| NCT05421546 | Completed | COVID-19|Vaccine Reaction |
University of Oxford |
August 1 2022 | Not Applicable |
| NCT04138134 | Active not recruiting | Venous Disease |
Neuromed IRCCS|Principal investigator: Giacomo Frati|Co-investigator: Francesco Pompeo |
February 1 2022 | -- |
| NCT04823806 | Active not recruiting | Depression|Healthy |
University Hospital Bonn |
December 1 2020 | Not Applicable |
| NCT02855918 | Completed | Major Depression |
University Hospital Montpellier|Institut National de la Santé Et de la Recherche Médicale France|Sys2Diag Mixt laboratory CNRS/Alcediag Montpellier |
September 23 2016 | Not Applicable |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.